Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...
Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...
Among patients with type 2 diabetes, use of GLP-1 agonists may increase the risks for adhesive capsulitis and required ...
Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.
The researchers reviewed 601 published trials of older people to investigate whether the efficacy of three medications — DPP-4 inhibitors, SGLT2 inhibitors, and GLP-1 agonists — was affected by the ...
Researchers looked at the nine people who had vision problems while using the drugs and is one of several that have ...
As demand remains high for GLP-1 drugs, primary care physicians are concerned about the risks of patients using third-party ...
Women prescribed a GLP-1 receptor agonist up to 2 years before conception were less likely to develop hypertensive disorders ...
Companies such as Teladoc and Omada Health have embraced GLP-1s while dangling the prospect of lowered costs to their ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback